PDF(Pubmed)
Abstract：
Remdesivir is a nucleotide prodrug of an adenosine analog. It binds to the viral Ribonucleic Acid (RNA)-dependent RNA polymerase and inhibits viral replication by terminating RNA transcription prematurely. Remdesivir has demonstrated in vitro and in vivo activity against Severe Acute Respiratory Syndrome Coronavirus 2; it also acts in vitro neutralization activity against the Omicron variant and its subvariants. We reported a 54-years-old woman admitted with Coronavirus disease 2019. Considering to require a high fraction of inspired oxygen therapy (⩾0.6) and based on lung high resolution computed tomography, Remdesivir therapy was ordered for 5 days. She experienced palpitations and dizziness 2 days after starting Remdesivir therapy. Her QTc interval was prolonged on the electrocardiogram without any significant electrolyte abnormalities or concomitant use of medications. Although the cardiac side effects of Remdesivir therapy have been well documented, in a few cases reported the association between Remdesivir therapy and QTc interval prolongation. Since, QTc interval prolongation has the potential risk of sudden cardiac death, the clinicians should be aware of mentioned association and check electrocardiogram daily, as well as other laboratory exams.
摘要：
Remdesivir是腺苷类似物的核苷酸前药。它与病毒核糖核酸（RNA）依赖性RNA聚合酶结合，并通过过早终止RNA转录来抑制病毒复制。Remdesivir已证明对严重急性呼吸系统综合症冠状病毒2的体外和体内活性；它还对Omicron变体及其亚变体具有体外中和活性。我们报道了一名54岁的女性，她因2019年冠状病毒病入院。考虑到需要高比例的吸氧治疗（0.6）和基于肺部高分辨率计算机断层扫描，雷德西韦治疗订购5天。在开始Remdesivir治疗2天后，她出现心悸和头晕。心电图上她的QTc间期延长，没有任何明显的电解质异常或同时使用药物。虽然Remdesivir治疗的心脏副作用已经有很好的记录，在少数病例中报告了雷米西韦治疗与QTc间期延长之间的关联。因为,QTc间期延长具有心源性猝死的潜在风险,临床医生应该意识到上述关联，并每天检查心电图，以及其他实验室考试。
